Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1482-1487
DOI: 10.1002/acn3.70357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.03.2026. Verfasst von Kimberly H Markowitz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Genentech, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least one PRL on quantitative susceptibility mapping (QSM), 97 PRLs were identified. Before treatment, PRLs showed higher QSM values than non‐PRLs ( p = 0.001), indicating iron enrichment. After treatment, PRLs demonstrated a greater QSM reduction ( p < 0.001), with an accelerated decline in susceptibility. These findings suggest ocrelizumab may attenuate iron‐related inflammation in PRLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Weill Cornell Medicine, New York, New York, USA.
- Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
- Mathematics and Statistics, Cleveland State University, Cleveland, Ohio, USA.
- Feil Family Brain and Mind Institute, Weill Cornell Medicine, New York, New York, USA.
ORCID-Profile: Kimberly H Markowitz, Susan A Gauthier
Förderung
- NCATS NIH HHS
- Genentech
- National Center for Advancing Translational Sciences
Zitieren
APA
Markowitz, K. H., Safi, N. V., Pliska-Bloch, I., Kaunzner, U. W., Luu, H., Sisman, M., Wang, Y., Nguyen, T. D., Hurtado Rúa, S., & Gauthier, S. A. (2026). Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis. Annals of Clinical and Translational Neurology, 13(7), 1482-1487. https://doi.org/10.1002/acn3.70357
Vancouver
Markowitz KH, Safi NV, Pliska-Bloch I, Kaunzner UW, Luu H, Sisman M, et al. Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2026;13(7):1482-1487. doi:10.1002/acn3.70357
BibTeX
@article{Markowitz2026,
author = {Markowitz, Kimberly H and Safi, Neha V and Pliska-Bloch, Iliana and Kaunzner, Ulrike W and Luu, Ha and Sisman, Mert and Wang, Yi and Nguyen, Thanh D and Hurtado Rúa, Sandra and Gauthier, Susan A},
title = {Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {7},
pages = {1482--1487},
doi = {10.1002/acn3.70357}
}
EUVIMED